Company / Working Capital
Astria Therapeutics, Inc. Working Capital History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$315.5M
FY2024
5-year range
$39.9M / $315.5M
FY2020-FY2024
Trend
+31.8%
vs FY2023
Sector context
#135 of 213
Health Care
What the data says
At $316M, Astria Therapeutics, Inc.'s working capital ranks #135 of 213 in the Health Care sector. Working Capital has increased for 5 consecutive years, from $34M in FY2019 to $316M in FY2024.
Based on SEC 10-K filings.
$316M in FY2024 with a 5-year CAGR of +56.2%.
Improved from $219M to $316M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +37.3%
- 5-Year CAGR
- +56.2%
- 10-Year CAGR
- -
Sector benchmark
#135 of 213 in Health CareTop 63% of 213This company $315.5M Sector average $934.6M
▼
-66.2% below sector average
Key checks
Key Insights
- Astria Therapeutics, Inc.'s working capital has grown for 5 consecutive years.
- 5-year CAGR of +56.2%, indicating consistent growth.
- In FY2024, working capital increased 31.8% year-over-year.
- Ranks #135 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.45 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $315.5M | +31.8% |
| FY2023 | $239.4M | +9.5% |
| FY2022 | $218.6M | +79.4% |
| FY2021 | $121.9M | +205.2% |
| FY2020 | $39.9M | +17.7% |
| FY2019 | $33.9M | -2.4% |
| FY2018 | $34.7M | +203.5% |
| FY2017 | $11.4M | -63.3% |
| FY2016 | $31.2M | -44.1% |
| FY2015 | $55.8M | +417.0% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026